Abstract
THE membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes3. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex4,5. Discrepancies between results with anti-CD28 and anti-B7 antibodies have suggested the existence of a second ligand for CD28 and CTLA-4 (refs 3, 6–8). We have generated a monoclonal antibody, IT2, that reacts with a 70K glycoprotein (B70). B70 complementary DNA was cloned from a B-lymphoblastoid cell line library and encodes a new protein of the immunoglobulin superfamily with limited homology to B7. B70 is expressed on resting monocytes and dendritic cells and on activated, but not resting, T, NK and B lymphocytes. IT2 substantially inhibited the binding of a CTLA4–immunoglobulin fusion protein to human B-lymphoblastoid cell lines and, together with anti-B7 antibody, completely blocked CTLA-4 binding. Further IT2 efficiently inhibited primary allogeneic mixed lymphocyte responses. These findings indicate that B70 is a second ligand for CD28 and CTLA-4 and may play an important role for costimulation of T cells in a primary immune response.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yokochi, T., Holly, R. D. & Clark, E. A. J. Immun. 128, 823–827 (1982).
Freeman, G. J. et al. J. Immun. 143, 2714–2722 (1989).
Linsley, P. S., Clark, E. A. & Ledbetter, J. A. Proc. natn. Acad. Sci. U.S.A. 87, 5031–5035 (1990).
Linsley, P. S. et al. J. exp. Med. 173, 721–730 (1991).
Koulova, L., Clark, E. A., Shu, G. & Dupont, B. J. exp. Med. 173, 759–762 (1991).
Azuma, M., Cayabyab, M., Buck, D., Phillips, J. H. & Lanier, L. L. J. Immun. 149, 1115–1123 (1992).
Azuma, M., Cayabyab, M., Buck, D., Phillips, J. H. & Lanier, L. L. J. exp. Med. 175, 353–360 (1992).
Domlo, N. K., Linsley, P. S. & Ledbetter, J. A. Eur. J. Immun. 21, 1277–1282 (1991).
Lenschow, D. J. et al. Science 257, 789–792 (1992).
Linsley, P. S. et al. Science 257, 792–795 (1992).
Turka, L. A. et al. Proc. natn. Acad. Sci. U.S.A. 89, 11102–11105 (1992).
Azuma, M., Cayabyab, M., Phillips, J. H. & Lanier, L. L. J. Immun. 150, 2091–2101 (1993).
Freedman, A. S., Freeman, G. J., Rhynhart, K. & Nadler, L. M. Cell. Immun. 137, 429–437 (1991).
Valle, A., Aubry, J.-P., Durand, I. & Banchereau, J. Int. Immun. 3, 229–236 (1991).
Azuma, M., Yssel, H., Phillips, J. H., Spits, H. & Lanier, L. L. J. exp. Med. 177, 845–850 (1993).
Ranheim, E. A. & Kipps, T. J. J. exp. Med. 177, 925–935 (1993).
Young, J. W. et al. J. clin. Invest. 90, 229–237 (1992).
Norton, S. D. et al. J. Immun. 149, 1556–1561 (1992).
Lanier, L. L. & Recktenwald, D. J. Methods: A Companion to Meth. Enzym. 2, 192–199 (1991).
Aruffo, A. & Seed, B. Proc. natn. Acad. Sci. U.S.A. 84, 8573–8577 (1987).
Lanier, L. L., Ruitenberg, J. J. & Phillips, J. H. J. Immun. 141, 3478–3485 (1988).
Kato, K. et al. J. exp. Med. 176, 1241–1249 (1992).
Brunet, J.-F. et al. Nature 328, 267–270 (1987).
Linsley, P. S. et al. J. exp. Med. 174, 561–569 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Azuma, M., Ito, D., Yagita, H. et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366, 76–79 (1993). https://doi.org/10.1038/366076a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/366076a0
This article is cited by
-
CTLA-4 suppresses hapten-induced contact hypersensitivity in atopic dermatitis model mice
Scientific Reports (2023)
-
Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor
Cancer Immunology, Immunotherapy (2023)
-
Treatment of in vitro generated Langerhans cells with JAK-STAT inhibitor reduces their inflammatory potential
Clinical and Experimental Medicine (2022)
-
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Nature Reviews Clinical Oncology (2021)
-
Novel protein pathways in development and progression of pulmonary sarcoidosis
Scientific Reports (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.